Anticancer drug therapy for anaplastic thyroid cancer
Anaplastic thyroid cancer is one of the rarest subtypes of thyroid cancer, accounting for only 1–2% of all thyroid cancer cases. It is also one of the most aggressive: prognosis remains dismal and the disease-specific mortality rate is close to 100%. This rarity has markedly limited the availability...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2025-04-01
|
| Series: | European Thyroid Journal |
| Subjects: | |
| Online Access: | https://etj.bioscientifica.com/view/journals/etj/14/2/ETJ-24-0287.xml |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849316013514948608 |
|---|---|
| author | Naomi Kiyota Taiji Koyama Iwao Sugitani |
| author_facet | Naomi Kiyota Taiji Koyama Iwao Sugitani |
| author_sort | Naomi Kiyota |
| collection | DOAJ |
| description | Anaplastic thyroid cancer is one of the rarest subtypes of thyroid cancer, accounting for only 1–2% of all thyroid cancer cases. It is also one of the most aggressive: prognosis remains dismal and the disease-specific mortality rate is close to 100%. This rarity has markedly limited the availability of prospective trial results, and no standard chemotherapeutic option for unresectable or metastatic anaplastic thyroid cancer has yet been established. Nevertheless, combination therapy with a BRAF inhibitor and MEK inhibitor has shown encouraging efficacy in patients with BRAF V600E-mutated anaplastic thyroid cancer. Other novel treatments such as immune checkpoint inhibitors have also shown promising results. Owing to these therapeutic advances, the prognosis of anaplastic thyroid cancer appears to be gradually improving. However, further development of novel treatments for this rare malignancy requires the development of substantial infrastructure for international collaborative study. |
| format | Article |
| id | doaj-art-a064e190abfe40c3909e861dcfcd1047 |
| institution | Kabale University |
| issn | 2235-0802 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | European Thyroid Journal |
| spelling | doaj-art-a064e190abfe40c3909e861dcfcd10472025-08-20T03:51:59ZengBioscientificaEuropean Thyroid Journal2235-08022025-04-0114210.1530/ETJ-24-02871Anticancer drug therapy for anaplastic thyroid cancerNaomi Kiyota0Taiji Koyama1Iwao Sugitani2Department of Medical Oncology/Hematology, Kobe University Hospital, Kobe, JapanDepartment of Medical Oncology/Hematology, Kobe University Hospital, Kobe, JapanDepartment of Endocrine Surgery, Nippon Medical School, Tokyo, JapanAnaplastic thyroid cancer is one of the rarest subtypes of thyroid cancer, accounting for only 1–2% of all thyroid cancer cases. It is also one of the most aggressive: prognosis remains dismal and the disease-specific mortality rate is close to 100%. This rarity has markedly limited the availability of prospective trial results, and no standard chemotherapeutic option for unresectable or metastatic anaplastic thyroid cancer has yet been established. Nevertheless, combination therapy with a BRAF inhibitor and MEK inhibitor has shown encouraging efficacy in patients with BRAF V600E-mutated anaplastic thyroid cancer. Other novel treatments such as immune checkpoint inhibitors have also shown promising results. Owing to these therapeutic advances, the prognosis of anaplastic thyroid cancer appears to be gradually improving. However, further development of novel treatments for this rare malignancy requires the development of substantial infrastructure for international collaborative study.https://etj.bioscientifica.com/view/journals/etj/14/2/ETJ-24-0287.xmlanaplastic thyroid canceranticancer treatmentchemotherapymolecular targeted agentbraf v600eimmune checkpoint inhibitor |
| spellingShingle | Naomi Kiyota Taiji Koyama Iwao Sugitani Anticancer drug therapy for anaplastic thyroid cancer European Thyroid Journal anaplastic thyroid cancer anticancer treatment chemotherapy molecular targeted agent braf v600e immune checkpoint inhibitor |
| title | Anticancer drug therapy for anaplastic thyroid cancer |
| title_full | Anticancer drug therapy for anaplastic thyroid cancer |
| title_fullStr | Anticancer drug therapy for anaplastic thyroid cancer |
| title_full_unstemmed | Anticancer drug therapy for anaplastic thyroid cancer |
| title_short | Anticancer drug therapy for anaplastic thyroid cancer |
| title_sort | anticancer drug therapy for anaplastic thyroid cancer |
| topic | anaplastic thyroid cancer anticancer treatment chemotherapy molecular targeted agent braf v600e immune checkpoint inhibitor |
| url | https://etj.bioscientifica.com/view/journals/etj/14/2/ETJ-24-0287.xml |
| work_keys_str_mv | AT naomikiyota anticancerdrugtherapyforanaplasticthyroidcancer AT taijikoyama anticancerdrugtherapyforanaplasticthyroidcancer AT iwaosugitani anticancerdrugtherapyforanaplasticthyroidcancer |